REZILIENT3 Interim at Presidential Symposium: Phase 3 Verdict Pending, Payer Gauntlet Already Set

Cullinan to Host Event on Zipalertinib Phase 3 Lung Cancer Data

Cullinan Therapeutics announced it will host a virtual event on September 14, 2026, at 8:00 a.m. ET for analysts and institutional investors. The event will discuss results from the planned interim analysis of the Phase 3 REZILIENT3 trial, evaluating zipalertinib plus chemotherapy for lung cancer. These data were recently presented in Presidential Symposium 2 at the International Association for the Study of Lung Cancer’s 2026 World Conference on Lung Cancer. The company aims to provide further insights into the trial's outcomes.

• Cullinan Therapeutics is hosting a virtual event to delve into the results of the Phase 3 REZILIENT3 trial, which investigated zipalertinib in combination with chemotherapy. This event is specifically designed for analysts and institutional investors to provide a detailed discussion and context around the recently presented clinical data for lung cancer.
• The data being discussed at the virtual event were initially featured in a prominent Presidential Symposium 2 at the International Association for the Study of Lung Cancer’s (IASLC) 2026 World Conference on Lung Cancer (WCLC). This signifies the importance and potential impact of the interim analysis results within the oncology community.
• The REZILIENT3 trial is a Phase 3 study evaluating zipalertinib plus chemotherapy, with the virtual event providing an opportunity to discuss its planned interim analysis. Key company executives, including CEO Nadim Ahmed and CMO Jeffrey Jones, MD, MBA, will participate to offer expert insights and address investor questions regarding the trial's findings.

REZILIENT3: Key Design Parameters and Endpoints in Lung Cancer

Several recent trials have advanced the understanding of targeted and systemic therapies across NSCLC subtypes, spanning first-line and later-line settings with diverse molecular targets and endpoints. The studies below represent a cross-section of phase I–III designs evaluating efficacy, safety, and biomarker correlates in advanced and early-stage disease.

The Persistent Unmet Needs in Lung Cancer Treatment

Despite meaningful advances in targeted therapy and immunotherapy, lung cancer management continues to face critical gaps — particularly in overcoming acquired resistance, addressing CNS involvement, and optimizing treatment sequencing for molecularly defined subpopulations.

• Resistance to EGFR-targeted therapies remains a central unmet need. Secondary mutations (e.g., EGFR exon 20 T790M) and bypass receptor activation via AXL drive progression in patients on first-, second-, and third-generation TKIs, including osimertinib. Novel strategies under investigation include bispecific antibodies targeting both EGFR and AXL, as well as the amivantamab plus lazertinib combination evaluated in the MARIPOSA trial, which demonstrated superior efficacy over osimertinib monotherapy by suppressing escape routes such as MET amplifications and secondary EGFR mutations.

• Post-EGFR-TKI progression represents a population with limited options. A Bayesian network meta-analysis of 19 RCTs (4,039 participants) identified sacituzumab tirumotecan (Sac-TMT) and datopotamab deruxtecan (Dato-DXd) as leading options, with Sac-TMT showing an OS hazard ratio of 0.36 (95% CI 0.20–0.66) and a PFS hazard ratio of 0.20 (95% CI 0.13–0.30) versus conventional chemotherapy — statistically superior to ICI-based and bispecific antibody-based strategies across nearly all comparators.

• Rare oncogenic driver populations in NSCLC — including those harboring ROS1 rearrangements, METex14 skipping mutations, EGFR exon 20 insertions, KRAS G12C mutations, HER2 mutations, RET fusions, NTRK fusions, and BRAF mutations — represent underserved subgroups requiring dedicated molecular testing strategies and targeted agent development, as the treatment paradigm for these alterations continues to evolve rapidly.

• Brain metastases in SCLC constitute a distinct high-burden population, with CNS involvement developing in up to 80% of patients. Emerging agents targeting DLL3 and B7-H3 — including tarlatamab, I-Dxd, and ZL-1310 — have demonstrated intracranial response rates of 62.5%–71%, though limited blood-brain barrier penetration and treatment resistance remain major unmet needs. Radiotherapy approaches such as hippocampal-avoidance whole-brain radiotherapy and stereotactic radiosurgery are being refined to preserve neurocognitive function.

• Quality of life and real-world evidence gaps in SCLC management are increasingly recognized as unmet priorities. Rapid disease progression and treatment-related toxicity significantly affect patients' physical and mental well-being, while real-world evidence — though gaining traction — faces challenges from data heterogeneity, bias, and lack of methodological standardization that limit its integration into clinical decision-making.

Zipalertinib + Chemo: A Pivotal Moment for EGFR Exon 20 Insertion NSCLC

The upcoming virtual event from Cullinan Therapeutics, detailing the Phase 3 REZILIENT3 trial results for zipalertinib plus chemotherapy, marks a critical juncture for the treatment of EGFR exon 20 insertion-mutated non-small cell lung cancer (NSCLC). This specific mutation subtype has long presented a formidable challenge, characterized by its inherent resistance to conventional EGFR TKIs and a history of poor patient outcomes. While recent years have seen the emergence of targeted therapies like mobocertinib, amivantamab, and sunvozertinib, significant unmet needs persist, particularly for patients who have progressed on existing treatments.

Zipalertinib, an irreversible EGFR inhibitor, is designed to selectively target these difficult exon 20 insertions. The strategic decision to evaluate it in combination with chemotherapy in a Phase 3 setting is noteworthy, reflecting a broader trend in oncology to enhance efficacy through synergistic approaches. Positive data from REZILIENT3 could position this combination as a new, much-needed option, potentially reshaping the treatment algorithm for this patient population.

However, the path to market leadership is not without its complexities:

• The competitive landscape is rapidly evolving, with established and emerging therapies setting a high bar for efficacy. Amivantamab plus chemotherapy, for instance, has demonstrated robust first-line results, and other selective TKIs are gaining traction in pretreated settings. Zipalertinib's combination must show a compelling and differentiated clinical benefit.

• The addition of chemotherapy, while potentially boosting efficacy, introduces the risk of increased and overlapping toxicities. Balancing improved outcomes with a manageable safety profile will be paramount for clinical adoption, as other TKI-chemotherapy regimens have shown higher rates of severe adverse events.

• The heterogeneity of prior treatments among patients with EGFR exon 20 insertion mutations means that the trial's specific patient population and the generalizability of its results will be closely scrutinized. Efficacy may vary significantly depending on whether patients are treatment-naive, platinum-pretreated, or have received prior targeted therapies like amivantamab.

Ultimately, the insights shared from REZILIENT3 will not only determine zipalertinib's immediate future but also provide valuable guidance on the optimal sequencing and combination strategies for this challenging NSCLC subtype. The oncology community will be keenly watching for data that can truly move the needle for patients in this high-need area.